Role of peripheral eosinophilia in adverse cutaneous drug reactions

F. Drago, L. Cogorno, A. F. Agnoletti, A. Parodi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE: The objective of this retrospective study was to verify whether peripheral eosinophilia (PE) may be a marker of severity for adverse cutaneous drug reactions (ACDR). PATIENTS AND METHODS: We investigated sixty-three patients diagnosed as adverse cutaneous drug reactions for PE. All the patients underwent blood tests at baseline visit. Only patients that showed a very likely connection between ACDR and the suspected causative drug were enrolled in the study. RESULTS: We found that 11 out of 63 patients (17%) presented PE for values ≥ 0.6 ×109 cells/l or for a percentage of total leukocytes ≥6%. These patients with PE showed a longer recovery time, more severe cutaneous reactions and needed a systemic therapy. CONCLUSIONS: These outcomes prompt us to believe that peripheral eosinophilia may be an index of severity for adverse cutaneous drug reactions. Therefore, we suggest physicians to always detect the presence of peripheral eosinophilia in order to not underestimate the reaction and to promptly start an appropriate therapy.

Original languageEnglish
Pages (from-to)2008-2009
Number of pages2
JournalEuropean Review for Medical and Pharmacological Sciences
Volume19
Issue number11
Publication statusPublished - 2015

Fingerprint

Eosinophilia
Drug-Related Side Effects and Adverse Reactions
Skin
Hematologic Tests
Leukocytes
Retrospective Studies
Physicians
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adverse cutaneous drug reactions
  • Eosinophils
  • Peripheral eosinophilia
  • Prognosis
  • Severity index

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Role of peripheral eosinophilia in adverse cutaneous drug reactions. / Drago, F.; Cogorno, L.; Agnoletti, A. F.; Parodi, A.

In: European Review for Medical and Pharmacological Sciences, Vol. 19, No. 11, 2015, p. 2008-2009.

Research output: Contribution to journalArticle

Drago, F. ; Cogorno, L. ; Agnoletti, A. F. ; Parodi, A. / Role of peripheral eosinophilia in adverse cutaneous drug reactions. In: European Review for Medical and Pharmacological Sciences. 2015 ; Vol. 19, No. 11. pp. 2008-2009.
@article{9cf8df1f16264b498f421ced568f1a95,
title = "Role of peripheral eosinophilia in adverse cutaneous drug reactions",
abstract = "OBJECTIVE: The objective of this retrospective study was to verify whether peripheral eosinophilia (PE) may be a marker of severity for adverse cutaneous drug reactions (ACDR). PATIENTS AND METHODS: We investigated sixty-three patients diagnosed as adverse cutaneous drug reactions for PE. All the patients underwent blood tests at baseline visit. Only patients that showed a very likely connection between ACDR and the suspected causative drug were enrolled in the study. RESULTS: We found that 11 out of 63 patients (17{\%}) presented PE for values ≥ 0.6 ×109 cells/l or for a percentage of total leukocytes ≥6{\%}. These patients with PE showed a longer recovery time, more severe cutaneous reactions and needed a systemic therapy. CONCLUSIONS: These outcomes prompt us to believe that peripheral eosinophilia may be an index of severity for adverse cutaneous drug reactions. Therefore, we suggest physicians to always detect the presence of peripheral eosinophilia in order to not underestimate the reaction and to promptly start an appropriate therapy.",
keywords = "Adverse cutaneous drug reactions, Eosinophils, Peripheral eosinophilia, Prognosis, Severity index",
author = "F. Drago and L. Cogorno and Agnoletti, {A. F.} and A. Parodi",
year = "2015",
language = "English",
volume = "19",
pages = "2008--2009",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "11",

}

TY - JOUR

T1 - Role of peripheral eosinophilia in adverse cutaneous drug reactions

AU - Drago, F.

AU - Cogorno, L.

AU - Agnoletti, A. F.

AU - Parodi, A.

PY - 2015

Y1 - 2015

N2 - OBJECTIVE: The objective of this retrospective study was to verify whether peripheral eosinophilia (PE) may be a marker of severity for adverse cutaneous drug reactions (ACDR). PATIENTS AND METHODS: We investigated sixty-three patients diagnosed as adverse cutaneous drug reactions for PE. All the patients underwent blood tests at baseline visit. Only patients that showed a very likely connection between ACDR and the suspected causative drug were enrolled in the study. RESULTS: We found that 11 out of 63 patients (17%) presented PE for values ≥ 0.6 ×109 cells/l or for a percentage of total leukocytes ≥6%. These patients with PE showed a longer recovery time, more severe cutaneous reactions and needed a systemic therapy. CONCLUSIONS: These outcomes prompt us to believe that peripheral eosinophilia may be an index of severity for adverse cutaneous drug reactions. Therefore, we suggest physicians to always detect the presence of peripheral eosinophilia in order to not underestimate the reaction and to promptly start an appropriate therapy.

AB - OBJECTIVE: The objective of this retrospective study was to verify whether peripheral eosinophilia (PE) may be a marker of severity for adverse cutaneous drug reactions (ACDR). PATIENTS AND METHODS: We investigated sixty-three patients diagnosed as adverse cutaneous drug reactions for PE. All the patients underwent blood tests at baseline visit. Only patients that showed a very likely connection between ACDR and the suspected causative drug were enrolled in the study. RESULTS: We found that 11 out of 63 patients (17%) presented PE for values ≥ 0.6 ×109 cells/l or for a percentage of total leukocytes ≥6%. These patients with PE showed a longer recovery time, more severe cutaneous reactions and needed a systemic therapy. CONCLUSIONS: These outcomes prompt us to believe that peripheral eosinophilia may be an index of severity for adverse cutaneous drug reactions. Therefore, we suggest physicians to always detect the presence of peripheral eosinophilia in order to not underestimate the reaction and to promptly start an appropriate therapy.

KW - Adverse cutaneous drug reactions

KW - Eosinophils

KW - Peripheral eosinophilia

KW - Prognosis

KW - Severity index

UR - http://www.scopus.com/inward/record.url?scp=84942287936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942287936&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 2008

EP - 2009

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 11

ER -